Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 26, 2002
BIOJECT MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Oregon (State or other jurisdiction of incorporation) | 0-15360 (Commission File Number) | 93-1099680 (IRS Employer Identification No.) |
7620 S.W. Bridgeport Road, Portland, OR (Address of principal executive offices) | 97224 (Zip Code) |
Registrant’s telephone number, including area code:(503) 639-7221
No Change
(Former name or former address, if changed since last report)
Item 5. Other Events | ||||||||
Item 7. Financial Statements and Exhibits | ||||||||
SIGNATURE | ||||||||
EXHIBIT INDEX | ||||||||
Exhibit 99.1 |
Table of Contents
Item 5. Other Events
Attached to this Form 8-K as Exhibit 99.1 and incorporated into this Form 8-K by reference is the company’s press release dated February 26, 2002 announcing that Amgen Inc. has given notice to the company of its election not to pursue further development of Iject and B2000 devices.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
99.1 Press release dated February 26, 2002. |
1
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 27, 2002.
BIOJECT MEDICAL TECHNOLOGIES, INC. | ||
| ||
By: | /s/ Christine M. Farrell | |
Christine M. Farrell Controller and Secretary |
2
Table of Contents
EXHIBIT INDEX
Exhibit | Description | |||||
99.1 | Press release dated February 26, 2002. |